Carbimazole CLINICAL USE Treatment of hyperthyroidism DOSE IN NORMAL RENAL FUNCTION 5–40 mg daily PHARMACOKINETICS Molecular weight                           :186.2 %Protein binding                           :Unbound (methimazole is 5%) %Excreted unchanged in urine     : <12 (methimazole) Volume of distribution (L/kg)       :0.5 (methimazole)half-life – normal/ESRD (hrs)      :3–6.4 (methimazole)/Increased DOSE IN RENAL IMPAIRMENT GFR (mL/MIN) 20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES CAPD                :Not dialysed. Dose as in normal renal function HD                     :Not dialysed. Dose as in normal renal functionHDF/high flux   :Unknown dialysability. Dose as in normal renal functionCAV/VVHD      :Unknown dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS Potentially hazardous interactions with other drugsNone known ADMINISTRATION Reconstition– Route Oral Rate of Administration –Comments– OTHER INFORMATION Carbimazole is a prodrug which is rapidly and completely metabolised to methimazole the active moietyThere have been reports of glomerulonephritis associated with the development of antineutrophil cytoplasmic antibodies in patients receiving thiourea anti-thyroid drugs.